This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer

This study has been terminated.
(Administratively complete.)
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: September 7, 2004
Last updated: March 18, 2013
Last verified: March 2013
This phase II trial is studying how well depsipeptide (romidepsin) works in treating patients with recurrent ovarian epithelial or peritoneal cavity cancer. Drugs used in chemotherapy, such as depsipeptide (romidepsin), work in different ways to stop tumor cells from dividing so they stop growing or die. Depsipeptide (romidepsin) may also stop the growth of ovarian epithelial or peritoneal cavity cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for their growth

Condition Intervention Phase
Primary Peritoneal Cavity Cancer Recurrent Ovarian Epithelial Cancer Drug: romidepsin Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study Of Single Agent Depsipeptide (FK228) In Recurrent, Platinum Sensitive Adeno-Carcinoma Of The Ovary Or Peritoneum

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Response rate [ Time Frame: Up to 5 years ]
    Estimated as proportion of patients with complete or partial reduction in tumor burden.

  • Toxicity as assessed by CTCAE version 3.0 [ Time Frame: Up to 5 years ]
  • Time to progression [ Time Frame: From first treatment until the date of progression, assessed up to 5 years ]
  • Survival [ Time Frame: From first treatment until death or the last date of contact, assessed up to 5 years ]

Enrollment: 51
Study Start Date: September 2004
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (single-agent depsipeptide)
Patients receive depsipeptide (romidepsin) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: romidepsin
Other Names:
  • FK228
  • FR901228
  • Istodax

Detailed Description:


I. To estimate the response rate of recurrent, platinum-sensitive adenocarcinoma of the ovarian or peritoneal to depsipeptide (romidepsin).

II. To determine the toxicity of depsipeptide in this patient population.

OUTLINE: This is a multicenter study.

Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients are followed up for 5 years.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed primary ovarian epithelial or peritoneal cavity cancer

    • Histologic confirmation of recurrent disease not required
  • Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques (including palpation, plain x-ray, computed tomography [CT] scan, or magnetic resonance imaging [MRI]) OR ≥ 10 mm by spiral CT scan
  • Achieved a complete response after initial prior platinum-containing (cisplatin or carboplatin) chemotherapy regimen (e.g., conventional-dose therapy, high-dose therapy, consolidation therapy, or extended therapy after surgical or nonsurgical assessment)

    • Patients who have not received paclitaxel or docetaxel as initial therapy may receive a second regimen containing these drugs
    • No prior chemotherapy for persistent or recurrent disease, including re-treatment with the original regimen
  • Platinum-sensitive disease, defined as having a treatment-free interval with no evidence of progressive disease for > 6 but < 12 months after completion of a platinum-based regimen
  • No known brain metastases
  • Performance status - Eastern Cooperative Oncology Group (ECOG) 0-2
  • Performance status - Karnofsky 60-100%
  • More than 6 months
  • White blood cells (WBC) ≥ 3,000/mm^3
  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Bilirubin normal
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times upper limit of normal (ULN)
  • Creatinine ≤ 1.5 times ULN
  • Creatinine clearance ≥ 60 mL/min
  • No New York Heart Association class III or IV congestive heart failure
  • No myocardial infarction within the past year
  • No uncontrolled dysrhythmias
  • No poorly controlled angina
  • No history of serious ventricular arrhythmia (e.g., ventricular tachycardia or ventricular fibrillation, ≥ 3 beats in a row)
  • QTc interval < 500 msec
  • No other significant cardiac disease
  • Potassium normal
  • Magnesium normal
  • No uncontrolled electrolyte abnormality (hypokalemia and hypomagnesemia)
  • No ongoing or active infection requiring antibiotics
  • No history of allergic reactions attributed to compounds of similar chemical or biological composition to study drug
  • No neuropathy ≥ grade 2
  • No other uncontrolled illness
  • No psychiatric illness or social situation that would preclude study compliance
  • No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No prior monoclonal antibodies, cytokines, or signal transduction inhibitors for recurrent disease
  • No concurrent biologic therapy
  • See Disease Characteristics
  • More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) for the primary malignancy
  • No prior FR901228 (depsipeptide)
  • No other concurrent chemotherapy
  • More than 4 weeks since prior hormonal therapy for the primary malignancy
  • Concurrent estrogen replacement therapy allowed
  • More than 4 weeks since prior radiotherapy
  • No prior radiotherapy to > 25% of bone marrow
  • No concurrent radiotherapy
  • Recovered from all prior therapy
  • More than 4 weeks since prior noncytotoxic therapy for the primary malignancy
  • No other prior noncytotoxic therapy for recurrent disease
  • No concurrent combination anti-retroviral therapy for HIV-positive patients
  • No other concurrent drugs known to have histone deacetylase inhibitor activity (e.g., valproic acid)
  • No concurrent agents that cause QTc prolongation
  • No other concurrent investigational agents
  • No other concurrent anticancer agents
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00091195

United States, North Carolina
High Point Regional Hospital
High Point, North Carolina, United States, 27261
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States, 27157
Sponsors and Collaborators
National Cancer Institute (NCI)
Principal Investigator: Brigitte Miller Wake Forest University Health Sciences
  More Information

Responsible Party: National Cancer Institute (NCI) Identifier: NCT00091195     History of Changes
Obsolete Identifiers: NCT01645670, NCT01660282
Other Study ID Numbers: NCI-2012-01036
CCCWFU 83403
U10CA081851 ( U.S. NIH Grant/Contract )
Study First Received: September 7, 2004
Last Updated: March 18, 2013

Additional relevant MeSH terms:
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Peritoneal Neoplasms
Neoplasms by Histologic Type
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Abdominal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Peritoneal Diseases
Antibiotics, Antineoplastic
Antineoplastic Agents processed this record on August 22, 2017